Replay : An archived replay will be available for 30 days at www.gud-knight.com . About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gud-knight.com or www.sedar.com . Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Ther
Maverix Private Equity Announces Team Additions
News provided by
Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ - Maverix Private Equity, a Toronto-based private equity firm which recently announced an inaugural USD $500 million growth-fund, has today announced the addition of Michael Wasserman as a Managing Partner, joining Founder John Ruffolo and Mark Maybank. Michael is returning to Canada after 17 years at H.I.G Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management. Most recently, Michael was a Managing Director of H.I.G. BioHealth Partners, the firm s dedicated healthcare investment fund, where Michael sourced, executed and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies. Michael remains a Senior Advisor with H.I.G. In addition to his firm-wide responsibilities, Michael will be leading Maverix s inves
According to TipRanks.com, Gonsalves is ranked #356 out of 7474 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.42 average price target.
Based on Knight Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $55.19 million and net profit of $8.23 million. In comparison, last year the company earned revenue of $37.27 million and had a GAAP net loss of $6.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Monday s analyst upgrades and downgrades - The Globe and Mail theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.